Insider Buying: Nautilus Biotechnology (NASDAQ:NAUT) CEO Acquires 116,500 Shares of Stock

Key Points

• Sujal Patel, CEO of Nautilus Biotechnology, purchased 116,500 shares at an average price of $0.67, increasing his ownership stake by 1.15% to over 10 million shares valued at approximately $6.87 million.
• Nautilus Biotechnology's stock price recently fell 4.4% to $0.67, with seasonal trading patterns indicating a 52-week low of $0.62 and a high of $3.09.
• Institutional investors now hold 50.71% of Nautilus Biotechnology's stock, with notable increases in stakes from several hedge funds like Presidio Capital Management and XTX Topco Ltd.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CEO Sujal Patel bought 116,500 shares of the firm's stock in a transaction dated Friday, September 5th. The shares were acquired at an average price of $0.67 per share, with a total value of $78,055.00. Following the purchase, the chief executive officer directly owned 10,258,221 shares of the company's stock, valued at approximately $6,873,008.07. This trade represents a 1.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Nautilus Biotechnology Trading Down 4.4%

Shares of NAUT traded down $0.03 during mid-day trading on Tuesday, hitting $0.67. 210,811 shares of the company's stock were exchanged, compared to its average volume of 215,461. Nautilus Biotechnology, Inc. has a fifty-two week low of $0.62 and a fifty-two week high of $3.09. The firm has a market capitalization of $84.63 million, a P/E ratio of -1.29 and a beta of 1.42. The business's 50 day moving average is $0.73 and its two-hundred day moving average is $0.81.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. On average, equities research analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Institutional Investors Weigh In On Nautilus Biotechnology

Hedge funds have recently made changes to their positions in the business. Presidio Capital Management LLC boosted its stake in shares of Nautilus Biotechnology by 246.6% during the second quarter. Presidio Capital Management LLC now owns 34,664 shares of the company's stock worth $25,000 after buying an additional 24,664 shares during the period. XTX Topco Ltd acquired a new stake in Nautilus Biotechnology in the first quarter valued at about $31,000. Cubist Systematic Strategies LLC acquired a new stake in Nautilus Biotechnology in the fourth quarter valued at about $34,000. Callan Family Office LLC acquired a new stake in Nautilus Biotechnology in the second quarter valued at about $35,000. Finally, Fayez Sarofim & Co acquired a new stake in Nautilus Biotechnology in the first quarter valued at about $39,000. Institutional investors and hedge funds own 50.71% of the company's stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.